MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

NCT Number	NCT07493538
Lead Sponsor	Masonic Cancer Center, University of Minnesota
Conditions	AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment	132 participants
Start Date	2026-04-10
Primary Completion	2030-03 (estimated)
Study Completion	2035-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-16